On March 15, 2023 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, reported that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, FL and virtually (Press release, IMUNON, MAR 15, 2023, View Source [SID1234628783]). The immunotherapy, IMNN-001 (formerly GEN-1), is currently in Phase 2 development for the localized treatment of advanced ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract is titled "Efficacy of GEN-1, an interleukin-12 immune gene therapy, at different dose frequencies." Details of the presentation are as follows:

Session Category: Clinical Research Excluding Trials
Session Title: Immunomodulatory Agents and Interventions
Session Date and Time: Tuesday, April 18, 2023 (9:00 AM – 12:30 PM)
Location: Poster Section 40
Poster Board Number: 26
Published Abstract Number 4440
Presenter: Jean Boyer, Ph.D., Vice President of Preclinical Research, IMUNON

AACR abstracts were published yesterday afternoon and are now available on the AACR (Free AACR Whitepaper) website at www.aacr.org.